Recent patents of dipeptidyl peptidase IV inhibitors

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 11, 2011, Pages 1693-1741

  Mendieta, Laura ^a   Tarrago, Teresa ^a   Giralt, Ernest ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CD26; DPP IV; DPP IV inhibitors; Incretin molecules; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BENZOPYRAZOLE DERIVATIVE; CYCLOHEXANE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; INSULIN; ISOCARBOSTYRIL DERIVATIVE; ISOQUINOLINE DERIVATIVE; METFORMIN; NAPHTHYRIDINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERAZINONE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; QUINOXALINE DERIVATIVE; QUINOZALINE DERIVATIVE; SHR 1039; SHR 1040; SITAGLIPTIN; THIAZOLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME INHIBITION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; IC 50; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOPOROSIS; PATENT; PROTEIN DEGRADATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; PATENTS AS TOPIC;

EID: 80054933500     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.627325     Document Type: Article

References (164)

1. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24 (Pubitemid 29505281)
2. Rasmussen HB, Branner S, Wiberg FC, et al. Crystal s tructure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25 (Pubitemid 36034172)
3. Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94 (Pubitemid 36775376)
4. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-64 (Pubitemid 34205737)
5. Vivier I, Marguet D, Naquet P, et al. Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J Immunol 1991;147:447-54
6. Yu DM, Slaitini L, Gysbers V, et al. Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol 2011;73:102-11
7. Rogge L, Bianchi E, Biffi M, et al. Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet 2000;25:96-101 (Pubitemid 30257045)
8. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57 (Pubitemid 46711096)
9. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011;13(Suppl 1):89-94
10. Drucker DJ, Erlich P, Asa SL, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-16 (Pubitemid 26277138)
11. Sakurai Y, Shintani N, Hayata A, et al. Trophic effects of PACAP on pancreatic islets: a mini-review. J Mol Neurosci 2011;43:3-7
12. Chu JY, Cheng CY, Lee VH, et al. Secretin and body fluid homeostasis. Kidney Int 2011;79:280-7
13. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-72 (Pubitemid 27524596)
14. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7
15. Kos K, Baker AR, Jernas M, et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 2009;11:285-92
16. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann NY Acad Sci 2003;994:162-8 (Pubitemid 36793863)
17. O?Connor TM, O?Connell J, O?Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol 2004;201:167-80
18. Busso N, Wagtmann N, Herlling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005;166:433-42 (Pubitemid 40189040)
19. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9 (Pubitemid 30412807)
20. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43 (Pubitemid 46871135)
21. Barreto SG, Carati CJ, Toouli J, et al. The islet-acinar axis of the pancreas: more than just insulin. Am J Physiol Gastrointest Liver Physiol 2010;299:G10-22
22. Karin N. The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J Leukoc Biol 2010;88:463-73
23. Yu DM, Yao TW, Chowdhury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010;277:1126-44
24. Martin M, Huguet J, Centelles JJ, et al. Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J Immunol 1995;155:4630-43
25. UniProt Consortium. Ongoing and future developments at the universal protein resource. Nucleic Acids Res 2011;39:D214-19
26. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994;91:5657-61 (Pubitemid 24174387)
27. Lee KN, Jackson KW, Christiansen VJ, et al. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004;103:3783-8 (Pubitemid 38596296)
28. Abbott CA, McCaughan GW, Levy MT, et al. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem 1999;266:798-810 (Pubitemid 30010097)
29. Ishii T, Ohnuma K, Murakami A, et al. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001;98:12138-43 (Pubitemid 32959840)
30. Ohnuma K, Uchiyama M, Yamochi T, et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 2007;282:10117-31 (Pubitemid 47104635)
31. Ohnuma K, Yamochi T, Uchiyama M, et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA 2004;101:14186-91 (Pubitemid 39305051)
32. Cheng HC, Abdel-Ghany M, Pauli BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem 2003;278:24600-7 (Pubitemid 37548613)
33. Gonzalez-Gronow M, Grenett HE, Weber MR, et al. Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J 2001;355:397-407 (Pubitemid 32397799)
34. Girardi AC, Degray BC, Nagy T, et al. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 2001;276:46671-7
35. Davoodi J, Kelly J, Gendron NH, et al. The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics 2007;7:2300-10 (Pubitemid 47067213)
36. Shimizu Y, Shaw S. Lymphocyte interactions with extracellular matrix. FASEB J 1991;5:2292-9 (Pubitemid 21892906)
37. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35 (Pubitemid 23188160)
38. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75 (Pubitemid 41094285)
39. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010;90:131-40
40. Davidson JA. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010;85:S27-37
41. Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin Investig Drugs 2011;20:723-32
42. Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004;19:1345-51 (Pubitemid 39386791)
43. Sedo A, Duke-Cohan JS, Balaziova E, et al. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005;7:253-69 (Pubitemid 41646256)
44. Ospelt C, Mertens JC, Jungel A, et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010;62:1224-35
45. Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010;88:125-31
46. Umezawa H, Aoyagi T, Ogawa K, et al. Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. J Antibiot (Tokyo) 1984;37:422-5 (Pubitemid 14129498)
47. Demuth HU, Baumgrass R, Schaper C, et al. Dipeptidylpeptidase IV-inactivation with N-peptidyl-O-aroyl hydroxylamines. J Enzyme Inhib 1988;2:129-42
48. Flentke GR, Munoz E, Huber BT, et al. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 1991;88:1556-9 (Pubitemid 21916264)
49. Li J, Wilk E, Wilk S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch Biochem Biophys 1995;323:148-54
50. Augustyns K, Van der Veken P, Senten K, et al. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr Med Chem 2005;12:971-98 (Pubitemid 40443851)
51. Boduszek B, Oleksyszyn J, Kam CM, et al. Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J Med Chem 1994;37:3969-76 (Pubitemid 24379686)
52. Novo Nordisk A/S. WO0202560A2; 2002
53. Boehringer Ingelheim Pharma KG. WO02068420A1; 2002
54. Merck & Co. US6699871B2; 2004
55. F. Hoffmann-La Roche AG. US6166063; 2000
56. Bristol-Myers Squibb Co. US6395767B2;2002
57. Takeda. WO2005095381A1; 2005
58. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009;23:443-52
59. Danilova O, Li B, Szardenings AK, et al. Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorg Med Chem Lett 2007;17:507-10 (Pubitemid 46073735)
60. Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 2005;8:51-8 (Pubitemid 40797956)
61. Kirby M, Yu DM, O?Connor S, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2010;118:31-41
62. Lopez A, Tarrago T, Giralt E. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010. Expert Opin Ther Patent 2011;21:1023-44
63. Bristol-Myers Squibb Co. WO2007053819A2; 2007
64. National Health Research Institutes (Taiwan). US20070082932A1; 2007
65. National Health Research Institutes (Taiwan). WO2009111239A2; 2009
66. Tufts University. WO2008119005A1; 2008
67. Kainos Medicine, ICC. WO2008087560A2; 2008
68. Alantos Pharmaceuticals, I. WO2006116157A2; 2006
69. Merck & Co., I. WO2006009886A1; 2006
70. Merck & Co., I. WO2006127530A2; 2006
71. Novartis. WO2008077597A1; 2008
72. F. Hoffmann-La Roche AG. WO2006066770; 2006
73. Merck & Co., I. WO2006039325A2; 2006
74. F. Hoffmann-La Roche AG. WO2006066747A1; 2006
75. Cox JM, Harper B, Mastracchio A, et al. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007;17:4579-83 (Pubitemid 47058943)
76. Astellas Pharma. WO2006098342A1; 2006
77. Dong-A Pharm. D.-A. WO2008130151A1; 2008
78. Dong-A Pharm. US20100120790A1; 2010
79. Eli Lilly and Co. WO2007015767A1; 2007
80. Bristol-Myers Squibb Co. WO2006071762A2; 2006
81. Phenomix Corp. WO2006017292A1; 2006
82. Shanghai Hengrui Pharmaceutical Co. WO2008089636A1; 2008
83. Shanghai Hengrui Pharmaceutical Co. EP2133077A1; 2007
84. Bristol-Myers Squibb Co. WO2006127287A2; 2006
85. Bristol-Myers Squibb Co. WO2006071752A1; 2006
86. Merck & Co., I. WO2006078676A2; 2006
87. Boehringer Ingelheim Pharma KG. WO2008017670A1; 2008
88. Concert Pharmaceuticals. WO2008141021A1; 2008
89. Aurigene Discovery Technologies. WO2006134613A2; 2006
90. Peakdale Molecular. WO2008040974A1; 2008
91. Peakdale Molecular. WO2008040995A1; 2008
92. Sanofi-Aventis. WO2006111261A1; 2006
93. Dainippon Sumitomo Pharma. EP1690863A1; 2006
94. Dainippon Sumitomo Pharma. US20070105890A1; 2007
95. Sanofi-Aventis. WO2006015691A1; 2006
96. Sanofi-Aventis. WO2006015699A1; 2006
97. Sanofi-Aventis. WO2006015701A1; 2006
98. Sanofi-Aventis. WO2006015700A1; 2006
99. Boehringer Ingelheim Pharma KG. WO2006027204A1; 2006
100. Boehringer Ingelheim Pharma KG. WO2006029769; 2006
101. Boehringer Ingelheim Pharma KG. WO2009147125A1; 2009
102. Boehringer Ingelheim Pharma KG. WO2010086411A1 2010
103. Boehringer Ingelheim Pharma KG. US20100173916A1 2010
104. Boehringer Ingelheim Pharma KG. US20100204250A1 2010
105. Novartis. WO2007071738A1; 2007
106. Takeda. WO2006020017A2; 2006
107. Takeda. WO2007112347; 2007
108. Takeda. US7732446B1 2010
109. Bristol-Myers Squibb Co. WO2008064107; 2008
110. LG Life Sciences. WO2009082134A2; 2009
111. F. Hoffmann-La Roche AG. WO2006058628A2; 2006
112. Lubbers T, Bohringer M, Gobbi L, et al. 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2- aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007;17:2966-70 (Pubitemid 46702649)
113. Boehringer M, Fischer H, Hennig M, et al. Aryl- and heteroaryl- substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2010;20:1106-8
114. Merck & Co., I. WO2006058064; 2006
115. Merck & Co., I. WO2007024993; 2007
116. Edmondson SD, Mastracchio A, Cos JM, et al. Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg Med Chem Lett 2009;19:4097-101
117. Merck. WO2006023750A2; 2006
118. Santhera Pharmaceuticals. WO2006097175A1; 2006
119. Santhera Pharmaceuticals. WO2008028662A1; 2008
120. LG Life Sciences. WO2006104356A1; 2006
121. LG Life Sciences. WO2008093960A1; 2008
122. Eli Lilly and Co. WO2007015805; 2007
123. Eli Lilly and Co. WO2007015807; 2007
124. Panacea Biotec. WO2009093269; 2009
125. Takeda. WO2006068978A2; 2006
126. Glenmark Pharmaceuticals. WO20060400625A1; 2006
127. Glenmark Pharmaceuticals. WO2006011035A1; 2006
128. Glenmark Pharmaceuticals. WO2007099385A1; 2007
129. Santhera Pharmaceuticals. WO2006013104; 2006
130. Santhera Pharmaceuticals. WO2009003681; 2009
131. Orchid Research Laboratories. WO2008029217; 2008
132. Orchid Research Laboratories. WO2010079413; 2010
133. Ranbaxy Laboratories. WO07029086; 2007
134. Sattigeri JA, Andappan MM, Kishore K, et al. Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors. Bioorg Med Chem Lett 2008;18:4087-91
135. Singh S, Sethi S, Khanna V, et al. RBx- 0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. Eur J Pharmacol 2011;652:157-63
136. Concert Pharmaceuticals. WO2009045476; 2009
137. Glenmark Pharmaceuticals. WO2006090244; 2006
138. Matrix Laboratories. WO2007113634; 2007
139. Novartis. WO2009068531; 2009
140. Lupin. WO2009037719; 2009
141. Lupin. WO2010146597 2010
142. Susan Marie Royalty. WO2006012441; 2006
143. Susan Marie Royalty. WO2006012395; 2006
144. Susan Marie Royalty. US7842707; 2010
145. Phenomix Corp. US20060264401; 2006
146. Phenomix Corp. US20070185061; 2007
147. Phenomix Corp. US7317109; 2008
148. Phenomix Corp. US20070299036; 2007
149. Phenomix Corp. US20080182995; 2008
150. Phenomix Corp. WO2008027273; 2008
151. Phenomix Corp. WO2008144730; 2008
152. Phenomix Corp. WO2010107809; 2010
153. Phenomix Corp. US7674913; 2010
154. Phenomix Corp. US7576121; 2009
155. Phenomix Corp. US20080300413; 2008
156. Tufts University. WO2007100374; 2007
157. Tufts University. WO2008118848; 2008
158. Tufts University. WO2010099537; 2010
159. Connolly BA, Sanford DG, Chiluwal AK, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem 2008;51:6005-13
160. F. Hoffmann-La Roche AG. WO2007054577; 2007
161. Cadila Pharmaceuticals. WO2010029422; 2010
162. Kuhn-Wache K, Bar JW, Hoffmann T, et al. Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site. Biol Chem 2011;392:223-31
163. Ansorge S, Nordhoff K, Bank U, et al. Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem 2011;392:153-68
164. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011;34(Suppl 2):S276-8